Related Experiment Video
Updated: Mar 15, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Stroke prevention in atrial fibrillation
Ben Freedman1, Tatjana S Potpara2, Gregory Y H Lip3
1Heart Research Institute, Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia; Department of Cardiology and Anzac Research Institute, Concord Hospital, Concord, NSW, Australia.
Insights
Atrial fibrillation contributes significantly to ischemic strokes. Early detection and anticoagulant treatment for high-risk patients can prevent many strokes, improving patient outcomes.
Area of Science:
- Cardiology
- Neurology
- Public Health
Background:
- Atrial fibrillation (AF) is a major cause of ischemic stroke, accounting for a third of cases.
- Many AF-related strokes result from undiagnosed or undertreated conditions.
- These strokes are often severe, leading to significant disability or death.
Purpose of the Study:
- To highlight the preventable nature of AF-related strokes.
- To emphasize the importance of early AF detection and appropriate anticoagulation.
- To advocate for proactive stroke prevention strategies in AF patients.
Main Methods:
- Review of stroke registry data to identify AF prevalence and stroke causes.
- Analysis of current guidelines for AF screening and risk stratification.
- Evaluation of anticoagulant therapies and bleeding risk assessment tools.
Main Results:
- Unknown or untreated atrial fibrillation is a primary driver of ischemic strokes.
- Proactive screening and case finding can identify at-risk individuals.
- Validated risk scores (e.g., CHA2DS2-VASc) aid in treatment decisions.
Conclusions:
- Implementing systematic AF screening and treatment is crucial for stroke prevention.
- Anticoagulant therapy should be offered to most AF patients, guided by risk assessment.
- Long-term patient support is essential for treatment adherence and efficacy.
Abstract:
Atrial fibrillation is found in a third of all ischaemic strokes, even more after post-stroke atrial fibrillation monitoring. Data from stroke registries show that both unknown and untreated or under treated atrial fibrillation is responsible for most of these strokes, which are often fatal or debilitating. Most could be prevented if efforts were directed towards detection of atrial fibrillation before stroke occurs, through screening or case finding, and treatment of all patients with atrial fibrillation at increased risk of stroke with well-controlled vitamin K antagonists or non-vitamin K antagonist anticoagulants. The default strategy should be to offer anticoagulant thromboprophylaxis to all patients with atrial fibrillation unless defined as truly low risk by simple validated risk scores, such as CHA2DS2-VASc. Assessment of bleeding risk using the HAS-BLED score should focus attention on reversible bleeding risk factors. Finally, patients need support from physicians and various other sources to start anticoagulant treatment and to ensure adherence to and persistence with treatment in the long term.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:26Coronary Artery Disease IV: Preventive Measures
01:25Dysrhythmias VI: Management of Dysrhythmias
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...